Text Size

The Effects of Exercise on Adipokine in Impaired Fasting Glucose or Impaired Glucose Tolerance Patients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2007 by Yonsei University.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Yonsei University
ClinicalTrials.gov Identifier:
NCT00472342
First received: May 10, 2007
Last updated: NA
Last verified: May 2007
History: No changes posted
  Purpose

Many adipokines are thought that related with metabolic disturbance such as glucose intolerance, dyslipidemia, and insulin resistance. It is reported that regular physical training could prevent the progression of diabetes from prediabetes and improve the insulin resistance. After physical training, many adipokine levels were changed due to improving insulin resistance.

In this study, we will examine the various adipokine levels such as adiponectin, RBP-4, and adrenomedullin after exercise training through exercise prescription in IFG and IGT patients.


Condition Intervention
Impaired Glucose Tolerance
Diabetes
 Behavioral: exercise prescription

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: The Effects of Exercise on Adipokine in Impaired Fasting Glucose or Impaired Glucose Tolerance Patients

Resource links provided by NLM:

Drug Information available for: Dextrose
U.S. FDA Resources

Further study details as provided by Yonsei University:

Primary Outcome Measures:
  • Improvements of adipokine levels [ Time Frame: 6 Months ]

Secondary Outcome Measures:
  • Prevention of diabetes [ Time Frame: 1~5 year ]

Estimated Enrollment: 182
Study Start Date: March 2007
Estimated Study Completion Date: December 2007
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   30 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age; 30~70
  2. Subjects with IGT and IFG
  3. Subjects with having possibility of exercise stress test
  4. Subjects with having a strong will to this study

Exclusion Criteria:

  1. Age <30 or >70
  2. Cr more than 1.5 mg/dL
  3. AST, ALT levels more than twice as upper normal range
  4. Subjects having past history of coronary artery disease
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00472342

Contacts
Contact: Choon Hee Chung, Prefessor 82-33-741-0506 cchung@yonsei.ac.kr

Locations
Korea, Republic of
Mi Young Lee Recruiting
Wonju, Kangwon-Do, Korea, Republic of, 220-701
Contact: Mi Young Lee, Dr     82-33-741-0681     domoe46@yonsei.ac.kr    
Sponsors and Collaborators
Yonsei University
Investigators
Principal Investigator: Mi Young Lee, Dr Department of Internal Medicine, Yonsei University Wonju College of Medicine
Study Chair: Choon Hee Chung, professor Department of Internal Medicine, Yonsei Univerisity Wonju College of Medicine
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00472342     History of Changes
Other Study ID Numbers: kenshin46
Study First Received: May 10, 2007
Last Updated: May 10, 2007
Health Authority: South Korea: Institutional Review Board

Keywords provided by Yonsei University:
impaired glucose tolerance
impaired fasting glucose
diabetes
adipokine
 adiponectin
RBP-4
adrenomedullin

Additional relevant MeSH terms:
Diabetes Mellitus
Glucose Intolerance
Prediabetic State
Glucose Metabolism Disorders
 Metabolic Diseases
Endocrine System Diseases
Hyperglycemia

ClinicalTrials.gov processed this record on May 23, 2013